Comparison between Gaviscon and omeprazole for gastroesophageal reflux in pregnancy

Not Applicable

Active, not recruiting

• Conditions: Gastroesophageal reflux disease in pregnancy; Digestive System; Gastro-oesophageal reflux disease

• Registration Number: ISRCTN15239323
• Lead Sponsor: niversity Malaya Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-16
• Last Update Posted: 2021-02-16
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: Female
• Target Recruitment: 140

Inclusion Criteria

1. Pregnant women aged 18 - 40 years
2. Gestational age 14 weeks to less than 38 weeks
3. Able to provide signed and dated informed consent

Exclusion Criteria

1. Pregnant women younger than 18 years or older than 40 years
2. Gestational age less than 14 weeks and more than 38 weeks
3. Presence of alarm symptoms (dysphagia, odynophagia, aspiration pneumonia, dysphonia, recurrent or persistent cough, gastrointestinal bleeding, frequent nausea/vomiting, persistent pain, iron deficiency anemia, and weight loss)
4. Presence of underlying gastrointestinal disease pre-pregnancy
5. Hypersensitivity to Gaviscon or omeprazole or both
6. Participants who are already on Gaviscon or omeprazole or both
7. Unable to provide signed and dated informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified